Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
dc.contributor.author | Wang, M | |
dc.contributor.author | Rule, Simon | |
dc.contributor.author | Zinzani, PL | |
dc.contributor.author | Goy, A | |
dc.contributor.author | Casasnovas, O | |
dc.contributor.author | Smith, SD | |
dc.contributor.author | Damaj, G | |
dc.contributor.author | Doorduijn, JK | |
dc.contributor.author | Lamy, T | |
dc.contributor.author | Morschhauser, F | |
dc.contributor.author | Panizo, C | |
dc.contributor.author | Shah, B | |
dc.contributor.author | Davies, A | |
dc.contributor.author | Eek, R | |
dc.contributor.author | Dupuis, J | |
dc.contributor.author | Jacobsen, E | |
dc.contributor.author | Kater, AP | |
dc.contributor.author | Le Gouill, S | |
dc.contributor.author | Oberic, L | |
dc.contributor.author | Robak, T | |
dc.contributor.author | Jain, P | |
dc.contributor.author | Frigault, MM | |
dc.contributor.author | Izumi, R | |
dc.contributor.author | Nguyen, D | |
dc.contributor.author | Patel, P | |
dc.contributor.author | Yin, M | |
dc.contributor.author | Długosz-Danecka, M | |
dc.date.accessioned | 2021-09-20T12:54:13Z | |
dc.date.issued | 2019-09-26 | |
dc.identifier.issn | 0887-6924 | |
dc.identifier.issn | 1476-5551 | |
dc.identifier.uri | http://hdl.handle.net/10026.1/17870 | |
dc.description.abstract |
To the Editor: Bruton tyrosine kinase (BTK) inhibitors have greatly improved the spectrum of treatment options in mantle cell lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective, orally administered, and potent BTK inhibitor with limited off-target activity [5]. Acalabrutinib was approved in 2017 by the US Food and Drug Administration for the treatment of relapsed/refractory MCL based on clinical data from the open-label, multicenter, phase 2 ACE-LY-004 study of acalabrutinib 100 mg twice daily [1]. Here, we present updated results from the ACE-LY-004 study after a median 26-month follow-up. Eligibility criteria and study design were published previously (Supplementary methods) [1]. Analysis of minimal residual disease (MRD) was conducted after complete response (CR) or partial response (PR) was achieved using the quantitative ClonoSEQ next-generation sequencing (5 × 10−6) assay (Adpative Biotechnologies, Seattle, WA, USA) in consenting patients with available paired archival tumor and whole blood samples. Data are updated as of February 12, 2018. | |
dc.format.extent | 2762-2766 | |
dc.format.medium | Print-Electronic | |
dc.language | en | |
dc.language.iso | en | |
dc.publisher | Springer Nature [academic journals on nature.com] | |
dc.subject | Adult | |
dc.subject | Agammaglobulinaemia Tyrosine Kinase | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Antineoplastic Agents | |
dc.subject | Benzamides | |
dc.subject | Cell Proliferation | |
dc.subject | Disease Progression | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Female | |
dc.subject | Follow-Up Studies | |
dc.subject | Humans | |
dc.subject | Ki-67 Antigen | |
dc.subject | Lymphoma, Mantle-Cell | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Neoplasm Recurrence, Local | |
dc.subject | Neoplasm, Residual | |
dc.subject | Pyrazines | |
dc.subject | Time Factors | |
dc.subject | Treatment Outcome | |
dc.title | Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma | |
dc.type | journal-article | |
dc.type | Clinical Trial, Phase II | |
dc.type | Letter | |
dc.type | Multicenter Study | |
dc.type | Research Support, Non-U.S. Gov't | |
plymouth.author-url | https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000495104300024&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008 | |
plymouth.issue | 11 | |
plymouth.volume | 33 | |
plymouth.publication-status | Published | |
plymouth.journal | Leukemia | |
dc.identifier.doi | 10.1038/s41375-019-0575-9 | |
plymouth.organisational-group | /Plymouth | |
plymouth.organisational-group | /Plymouth/Faculty of Health | |
plymouth.organisational-group | /Plymouth/Faculty of Health/Peninsula Medical School | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine/UoA01 Clinical Medicine | |
plymouth.organisational-group | /Plymouth/Research Groups | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED) | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR | |
plymouth.organisational-group | /Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CCT&PS | |
plymouth.organisational-group | /Plymouth/Users by role | |
plymouth.organisational-group | /Plymouth/Users by role/Academics | |
dc.publisher.place | England | |
dcterms.dateAccepted | 2019-07-19 | |
dc.rights.embargodate | 2021-9-21 | |
dc.identifier.eissn | 1476-5551 | |
dc.rights.embargoperiod | Not known | |
rioxxterms.versionofrecord | 10.1038/s41375-019-0575-9 | |
rioxxterms.licenseref.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
rioxxterms.licenseref.startdate | 2019-09-26 | |
rioxxterms.type | Journal Article/Review |